Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 31, 2024 08:00 ET | Source: Barinthus Biotherapeutics

Barinthus Bio Announces Late Breaking Presentation at AASLD 2024 – The Liver Meeting® and Attendance at November Conferences

Barinthus Bio Announces Late Breaking Presentation at AASLD 2024 – The Liver Meeting® and Attendance at November Conferences
October 01, 2024 08:00 ET | Source: Barinthus Biotherapeutics

Barinthus Bio Completes Enrollment for Phase 2b HBV003 Clinical Trial in Chronic Hepatitis B and Phase 1 PCA001 Clinical Trial in Prostate Cancer

Barinthus Bio Completes Enrollment for Phase 2b HBV003 Clinical Trial in Chronic Hepatitis B and Phase 1 PCA001 Clinical Trial in Prostate Cancer
September 24, 2024 08:00 ET | Source: Barinthus Biotherapeutics

Barinthus Bio Initiates Phase 1 Clinical Trial of VTP-1000 for the Treatment of Celiac Disease

Barinthus Bio Initiates Phase 1 Clinical Trial of VTP-1000 for the Treatment of Celiac Disease
August 08, 2024 08:00 ET | Source: Barinthus Biotherapeutics

Barinthus Bio Reports Second Quarter 2024 Update on Corporate Developments and Financial Results

Barinthus Bio Reports Second Quarter 2024 Update on Corporate Developments and Financial Results
June 12, 2024 16:01 ET | Source: Barinthus Biotherapeutics

Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections

Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections
June 06, 2024 11:15 ET | Source: Barinthus Biotherapeutics

Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B

Barinthus Bio presents updated data from two clinical trials in people with chronic hepatitis B at EASL Congress 2024.
May 22, 2024 08:00 ET | Source: Barinthus Biotherapeutics

Barinthus Bio to Present VTP-300 Clinical Data Updates at EASL Congress 2024

Two abstracts highlighting the Company's lead hepatitis B-focused asset will be presented as poster and oral presentations.More mature interim data to be presented at EASL following abstract data cuts...
May 13, 2024 08:00 ET | Source: Barinthus Biotherapeutics

Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments

Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments
May 01, 2024 07:00 ET | Source: Barinthus Biotherapeutics

Barinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical Officer

Barinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical Officer.
April 18, 2024 16:10 ET | Source: Barinthus Biotherapeutics

Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections

Barinthus Biotherapeutics plc (NASDAQ: BRNS), formerly Vaccitech plc, today announced topline final data from the APOLLO trial (also known as HPV001).